Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - caspofungin - pdr/conc/soln for infus - 50 milligram(s) - other antimycotics for systemic use; caspofungin

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - caspofungin - pdr/conc/soln for infus - 70 milligram(s) - other antimycotics for systemic use; caspofungin

Ireland - English - HPRA (Health Products Regulatory Authority)

ethypharm - caspofungin - powder for concentrate for solution for infusion - 50.00 milligram(s) - other antimycotics for systemic use; caspofungin

Ireland - English - HPRA (Health Products Regulatory Authority)

ethypharm - caspofungin - powder for concentrate for solution for infusion - 70.00 milligram(s) - other antimycotics for systemic use; caspofungin

Ireland - English - HPRA (Health Products Regulatory Authority)

pinewood laboratories ltd - caspofungin - powder for concentrate for solution for infusion - 50 milligram(s) - other antimycotics for systemic use; caspofungin

Ireland - English - HPRA (Health Products Regulatory Authority)

pinewood laboratories ltd - caspofungin - powder for concentrate for solution for infusion - 70 milligram(s) - other antimycotics for systemic use; caspofungin

Israel - English - Ministry of Health

merck sharp & dohme israel ltd - caspofungin as acetate - powder for concentrate for solution for infusion - caspofungin as acetate 50 mg/vial - caspofungin - caspofungin - cancidas is indicated in adults and pediatric patients (3 months and older) for:- empirical therapy for presumed fungal infections in febrile, neutropenic patients.- treatment of candidemia and the following candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. cancidas has not been studied in endocarditis, ostemyelitis, and meningitis due to candida.- treatment of esophageal candidiasis.- treatment of invasive aspergillosis in patients who are refractory to or intolerant to other therapies (i.e. amphotericin b, lipid formulations of amphotericin b, and/or itraconazole). cancidas has not been studied as initial therapy for invasive aspergillosis.

Israel - English - Ministry of Health

merck sharp & dohme israel ltd - caspofungin as acetate - powder for concentrate for solution for infusion - caspofungin as acetate 70 mg/vial - caspofungin - caspofungin - cancidas is indicated in adults and pediatric patients (3 months and older) for:- empirical therapy for presumed fungal infections in febrile, neutropenic patients.- treatment of candidemia and the following candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. cancidas has not been studied in endocarditis, ostemyelitis, and meningitis due to candida.- treatment of esophageal candidiasis.- treatment of invasive aspergillosis in patients who are refractory to or intolerant to other therapies (i.e. amphotericin b, lipid formulations of amphotericin b, and/or itraconazole). cancidas has not been studied as initial therapy for invasive aspergillosis.

Singapore - English - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - caspofungin acetate eqv caspofungin - injection, powder, for solution - 50 mg - caspofungin acetate eqv caspofungin 50 mg/vial

Singapore - English - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - caspofungin acetate eqv caspofungin - injection, powder, for solution - 70 mg/vial - caspofungin acetate eqv caspofungin 70 mg/vial